In pediatric B-cell acute lymphoblastic leukemia, specific genetic mutations present in a patient’s tumor at initial diagnosis correlate with the risk of disease recurrence, with those risk profiles varying according to leukemia subtype. Published in Blood, the investigation evaluated paired diagnostic and relapse DNA specimens from 183 children, marking the largest comparative cohort assembled to analyze subtype-level genomic determinants of recurrence in this malignancy.
The research was conducted by investigators at St. Jude Children’s Research Hospital and Seattle Children’s Hospital in collaboration with the Children’s Oncology Group. Modern therapeutic regimens achieve overall survival rates surpassing 90% in pediatric B-cell acute lymphoblastic leukemia, yet clinical outcomes deteriorate substantially when the disease recurs. Although clinicians currently classify the cancer into distinct genetic subtypes to select initial therapy, the authors sought to determine whether additional baseline mutations could explain subsequent treatment failures and refine upfront risk stratification.
A central observation from the genomic analysis is that certain leukemic clones possess resistance-conferring alterations prior to any therapeutic exposure. Corresponding author Xiaotu Ma, PhD, of the St. Jude Department of Computational Biology, noted that the data verified that specific tumors are inherently resistant to conventional frontline therapy from the outset. Identifying these baseline resistance markers could allow clinical oncologists to stratify patients into intensified regimens before therapy commences, potentially preventing relapses before they emerge.
By comparing matched genomic sequences from initial diagnosis and subsequent relapse across the 183 pediatric cases, the research team demonstrated that a mutation’s prognostic weight depends on the broader genetic subtype of the leukemia. Ma highlighted that the investigators had initially hypothesized discovering universal resistance mutations that increased relapse vulnerability across all forms of B-ALL. Instead, the comparative cohort revealed that relapse-associated mutations operate in a subtype-specific manner, requiring risk interpretation within each patient’s specific genomic background.
The diagnostic utility of subtype-specific alterations was clearly demonstrated within the ETV6::RUNX1 leukemia subtype, a group historically characterized by favorable patient prognoses. Genomic profiling showed that patients harboring a fusion between exon 5 of ETV6 and exon 4 of RUNX1 experienced a significantly higher probability of relapse compared with individuals carrying the dominant subtype transcript, which joins exon 5 of ETV6 with exon 3 of RUNX1.
First author Yuan Feng, PhD, also of the St. Jude Department of Computational Biology, emphasized that patients with the exon 5-to-exon 4 fusion experienced relapses more rapidly than those with standard fusion transcripts. Because rapid disease recurrence reflects more aggressive biological behavior, Feng pointed out that this molecular distinction could inform prospective clinical protocol design, potentially warranting higher-intensity therapy for patients identified with these higher-risk fusion structures at diagnosis.
Beyond the ETV6::RUNX1 cohort, the research team identified additional genetic alterations linked to heightened relapse risk across other leukemia subtypes. Together, this collection of mutations provides a roadmap to better predict which patients at diagnosis are at the highest risk of recurrence.
The paired genomic comparisons also uncovered that approximately 3% of cases clinically diagnosed and recorded as relapses were not recurrent manifestations of the original leukemia clone. Co-first author Hanxia Li, PhD, explained that biological sequencing proved these events were actually second, genetically distinct primary cancers, which in some instances arose in the setting of underlying genetic predispositions or other oncogenic factors.
Differentiating between true clonal recurrence and an independent second malignancy carries immediate implications for therapeutic selection. Li observed that patients diagnosed with biologically novel malignancies do not require intensive relapse protocols, which carry considerable toxicity; instead, they can often be effectively treated and cured with frontline therapeutic regimens that involve fewer long-term adverse side effects.
Collectively, the study underscores the clinical importance of interrogating genomic alterations present at baseline rather than focusing exclusively on mutations that arise under selective treatment pressure. Ma explained that discovering clinically actionable genomic insights at initial presentation provides clinicians with an opportunity to optimize patient management and implement targeted preventive strategies before disease recurrence occurs.
The investigation brought together extensive inter-institutional expertise, with computational biology leadership from St. Jude co-first authors Yuan Feng, Hanxia Li, Heather Mulder, and Ying Shao, alongside co-corresponding author Mignon Loh representing Seattle Children’s Hospital and the University of Washington. Multi-institutional collaboration through the Children’s Oncology Group engaged investigators across institutions including Nationwide Children’s Hospital, the Children’s Hospital of Philadelphia, Stony Brook Children’s, and the University of California San Francisco.
Support for the research was provided by multiple grants from the National Cancer Institute—including operations and statistics support for the National Clinical Trials Network—as well as the St. Baldrick’s Foundation, the Fund for Innovation in Cancer Informatics, and ALSAC, the fundraising organization of St. Jude Children’s Research Hospital.
The Children’s Oncology Group study was published in the journal Blood under the title "Identifying novel genomic alterations in relapsed childhood B-ALL: a report from the Children’s Oncology Group" under digital object identifier 10.1182/blood.2025032369.
Subject of Research: Subtype-specific genomic alterations and relapse risk in pediatric B-cell acute lymphoblastic leukemia
Article Title: Subtype-specific mutations drive relapse risk in most common childhood leukemia
Article References: Subtype-specific mutations drive relapse risk in most common childhood leukemia. Original publication (Bibliographic details unavailable.)
Image Credits: AI Generated
DOI: Not provided
Keywords: B-cell acute lymphoblastic leukemia, pediatric leukemia, leukemia relapse, subtype-specific mutations, ETV6::RUNX1 fusion, exon fusion transcripts, therapy resistance mutations, treatment stratification, second primary cancers, Children's Oncology Group, St. Jude Children's Research Hospital, Seattle Children's Hospital, Blood journal, computational biology, frontline treatment protocol, high-intensity cancer therapy, paired genomic sequencing
News Source: Nathaniel Bowman. (November 14, 2026). Diagnostic Genetic Alterations Predict Subtype-Specific Relapse in Childhood B-Cell Leukemia. Scienmag.



